Showing results (151-160 of 172) with videos related to

Sort By:
Pageof 18
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 28, 2019
Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609Ahmad A Tarhini, Sandra J Lee, F Stephen Hodi, et al.
Annals of Surgical Oncology|October 31, 2025
Recurrence and Survival Outcomes in Patients with Primary Merkel Cell Carcinoma with Positive, Negative, or Not Performed Sentinel Lymph Node BiopsyMichelle M Dugan, Caitlyn Balsay-Patel, Nicholas Chin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 1, 2019
Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma studyL Khoja, E G Atenafu, S Suciu, et al.
Biorxiv : the Preprint Server for Biology|July 15, 2025
Primary tumor microbiomes predict distant metastasis of colorectal cancerBishal Parajuli, Vishal Midya, Ryan Kiddle, et al.
Cancer Research Communications|July 17, 2024
The Tumor Microbiome as a Predictor of Outcomes in Patients with Metastatic Melanoma Treated with Immune Checkpoint InhibitorsCaroline E Dravillas, Samuel S Coleman, Rebecca Hoyd, et al.
NPJ Precision Oncology|November 25, 2025
Primary tumor microbiomes predict distant metastasis of colorectal cancerBishal Parajuli, Vishal Midya, Ryan Kiddle, et al.
Neuro-Oncology|April 21, 2021
Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204)Hussein A Tawbi, Peter A Forsyth, F Stephen Hodi, et al.
Nature Medicine|October 18, 2025
Adjuvant nivolumab and relatlimab in stage III/IV melanoma: the randomized phase 3 RELATIVITY-098 trialGeorgina V Long, Charlie Garnett-Benson, Sonia Dolfi, et al.
Cancer Cell|January 16, 2019
An Interferon-Driven Oxysterol-Based Defense against Tumor-Derived Extracellular VesiclesAngelica Ortiz, Jun Gui, Farima Zahedi, et al.
Nature Medicine|February 9, 2021
Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)Alexander M Menzies, Rodabe N Amaria, Elisa A Rozeman, et al.
Pageof 18